Primary Melanoma of the Lacrimal Sac Treated With Pembrolizumab.
| Autor: | Salloum G; Tennessee Oculoplastics, Nashville, Tennessee, U.S.A., Dryden S; Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee-Memphis, Memphis, Tennessee, U.S.A., Meador AG; Tennessee Oculoplastics, Nashville, Tennessee, U.S.A., Kurochkin PD; Department of Ophthalmology, SUNY Upstate, Syracuse, New York, U.S.A., Chamberlain BK; PathGroup, Brentwood, Tennessee, U.S.A., Fasig JH; PathGroup, Brentwood, Tennessee, U.S.A., Waynick CA; Tennessee Oncology, Nashville, Tennessee, U.S.A., Wesley RE; Tennessee Oculoplastics, Nashville, Tennessee, U.S.A., Everman KR; Tennessee Oculoplastics, Nashville, Tennessee, U.S.A. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2021 May-Jun 01; Vol. 37 (3), pp. e111-e112. |
| DOI: | 10.1097/IOP.0000000000001868 |
| Abstrakt: | Primary melanoma of the lacrimal sac is a rare entity, with high mortality and a propensity for recurrence. This report details a patient with widely metastatic melanoma discovered after biopsy of abnormal lacrimal sac tissue during routine dacryocystorhinostomy. The patient subsequently underwent local excision and treatment with pembrolizumab. At the time of this writing, it has been 24 months since the original diagnosis with resolution of his lacrimal and orbital lesions and improvement in all metastatic lesions. This case highlights the growing use of cancer genomics and immunotherapeutic agents in orbital aspects of oncology and reinforces the role of a multidisciplinary approach in the treatment of such diseases. Competing Interests: The authors have no financial or conflicts of interest to disclose. (Copyright © 2020 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|